Cipla reported a record consolidated revenue of INR 7,119 crore for the first quarter of FY27 (Q1FY27), driven by double-digit growth in its One India business and new product launches in North America. Despite the top-line milestone, profitability metrics contracted significantly year-on-year, with EBITDA falling to INR 1,192 crore (margin 16.7%) from INR 1,778 crore (25.6%) in Q1FY26, and PAT declining to INR 789 crore (11.1%) from INR 1,298 crore (18.7%). The company maintained its full-year FY27 EBITDA margin guidance of 18.5% to 20%, citing upcoming pipeline approvals.

Financial Performance Snapshot

The revenue growth was broad-based, with One India contributing the largest share at 48% of total revenue. The region posted its highest-ever quarterly revenue of INR 3,452 crore, representing a 12% year-on-year increase. North America contributed 22% ($162 million), while Emerging Markets & Europe and One Africa each accounted for 14%.

The decline in margins was primarily attributed to higher material costs (INR 2,667 crore vs INR 2,171 crore in Q1FY26) and increased employee benefits expenses (INR 1,497 crore vs INR 1,312 crore). Other operating income also dropped sharply to INR 42 crore from INR 120 crore in the prior year.

Regional Business Updates

One India: Chronic Therapies Lead Growth

One India’s branded prescription segment maintained its #2 rank in overall chronic therapies, with the chronic mix improving to 60.4%. Key therapeutic areas saw double-digit growth: Anti-diabetic (+26%), Cardiac (+14%), Respiratory (+13%), Dermatology (+11%), and Urology (+10%). The company launched several new products, including Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash. Its flagship respiratory brand, Foracort, crossed the INR 1,000 crore mark. In consumer health, anchor brands Nicotex, Omnigel, and Cipladine retained market leadership.

North America: gVentolin Launch

Cipla launched its first AB-rated generic Ventolin (gVentolin) in the US market during the quarter, with initial shipments executed. The company plans a supply ramp-up over coming quarters. This launch is critical to achieving its target of a $1 billion run rate for the North America business by FY27. Additionally, gProventil ranked No. 1 in the overall US Albuterol MDI market with a 21% share. Other recent launches include Nintedanib, Dapagliflozin, and Liraglutide.

One Africa and Emerging Markets

In South Africa, the private label business grew faster than the market (1.2x), with prescription revenue growing 9.8% against a market growth of 6.9%. Cipla held an 8.8% market share in SA Prescription. Emerging Markets & Europe grew 5% YoY to $106 million.

Pipeline and ESG Progress

As of June 30, 2026, Cipla’s US pipeline included 103 approved ANDAs/NDAs, 19 tentatively approved, and 38 under approval. The total portfolio stands at 278 ANDAs/NDAs across all statuses. On the sustainability front, Cipla achieved 57% renewable electricity share for India manufacturing and maintained zero fatalities in operations. Its South Africa manufacturing unit achieved Net Zero Waste Certification.

What the Numbers Show

While top-line growth confirms demand resilience, the sharp contraction in EBITDA and PAT margins highlights cost inflation pressures and a drop in other income. The divergence between revenue growth (+2.3%) and profit decline (-39% PAT) suggests that operational efficiencies have not yet offset rising input costs. However, management’s retention of the 18.5–20% FY27 EBITDA margin guidance implies confidence that new launches, particularly gVentolin in the US, will drive margin recovery in subsequent quarters.

Cipla Limited has appointed Dinesh Jain as its Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective July 24, 2026. The Board of Directors approved the appointment and associated changes in authorised officers under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, during a meeting held on July 23, 2026. This leadership transition aims to align the company’s financial strategy with its broader business objectives.

The Board meeting commenced at 9:15 a.m. IST and concluded at 1:00 p.m. IST on July 23, 2026. Consequently, Ashish Adukia ceased to be the Global CFO and KMP at the close of business hours on July 23, 2026, transitioning to an internal business leadership role within the company. The disclosure was made in compliance with SEBI Listing Regulations and published on the company’s website under the Investors Section.

Dinesh Jain brings over three decades of experience to the role, having previously served as Head – Corporate Finance at Cipla Limited. His expertise spans strategic planning, corporate finance, accounting, taxation, treasury, financial planning and analysis (FP&A), and corporate governance. He has also led significant initiatives in mergers, amalgamations, and corporate restructuring. As a qualified Chartered Accountant and member of the Institute of Chartered Accountants of India, Jain’s background in business valuation, fundraising, due diligence, regulatory matters, and stakeholder management is expected to support the company’s financial operations.

Updated Contact Details for KMPs and Authorised Officers

The following table lists the contact details for Cipla Limited’s Key Managerial Personnel and officers authorised under Regulation 30(5) of the SEBI Listing Regulations:

The appointment underscores Cipla’s focus on strengthening its financial leadership team to navigate complex regulatory environments and drive strategic growth.